Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novartis’s Cosentyx Suffers Rare Phase III Fail

03 Jul 2025

• By Kevin Grogan

(Novartis)

Related Content

Novartis Committed To Carving Out More Indications For Cosentyx

12 May 2023

Related Companies

Novartis AG

Roche Holding AG

AbbVie Inc.

Additional Topics

Research & Development

More from Scrip

More from Strategy

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.